The global dry eye syndrome market was worth US$ 3.5 Billion in 2018. Dry eye syndrome, medically known as keratoconjunctivitis sicca (KCS), is a term that defines the lack of lubrication or moisture on the surface of the infected person’s eyes. It is a commonly occurring disease which can affect almost anyone. Various symptoms of dry eye include aching and burning sensations, sore eyes, red eyes, fatigued eyes, itchy eyes, photophobia, etc. Apart from this, watery eyes can also be a symptom as the dry surface of the eyes over-stimulate the production of watery component of tears in order to reduce the dryness. There are several factors that can cause dry eye syndrome such as excessive computer use, allergies, aging, menopause, smoking, LASIK eye surgery, hormone replacement therapy, etc.
Various diseases, such as diabetes, thyroid disorders, Sjogren’s syndrome, lupus, scleroderma, rheumatoid arthritis, etc., are also contributing to the prevalence of dry eyes among people. As per statistics, around 425-430 Million individuals across the globe get affected by diabetes. It causes constant changes in the composition of patient’s blood which adversely affects the tear glands resulting in a rising prevalence of dry eye. Another key factor which is contributing to the growth of the market is the rising geriatric population. As per estimates, around 9% of the global population is above 65 years of age, and by 2050 this segment is expected to account for around 17% of the global population. With the prevalence of dry eyes being fairly high among the elderly, we expect the market for dry eye syndrome to exhibit a strong growth. Other factors augmenting the growth of this market include increasing awareness levels, rising diagnostic rates, better treatment options, etc. Looking forward, the market value is projected to reach US$ 5.1 Billion by 2024, exhibiting a CAGR of 6.5% during 2019-2024.
Market Summary:
Based on the disease type, the market has been segmented into evaporative dry eye syndrome and aqueous dry eye syndrome.
Based on the drug type, the market has been segmented into lubricant eye drops, anti-inflammatory drugs and autologous serum eye drops.
Based on the product type, the market has been segmented into liquid drops, gel, liquid wipes, eye ointment and others.
Based on the distribution channels, the market has been segmented into retail pharmacies, hospital pharmacies and online pharmacies.
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The competitive landscape of the market has also been examined with some of the key players being Novartis AG, Allergan plc., Otsuka Holdings Co., Ltd., Santen Pharmaceutical Co., Ltd., Nicox S.A., Auven Therapeutics, Akorn, Inc., Bausch + Lomb, Alimera Science and GlaxoSmithKline plc.
This report provides a deep insight into the global dry eye syndrome market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the dry eye syndrome market in any manner.
Key Questions Answered in This Report:
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Properties 4.3 Key Industry Trends 5 Global Dry Eye Syndrome Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Disease Type 5.4 Market Breakup by Drug Type 5.5 Market Breakup by Product 5.6 Market Breakup by Distribution Channels 5.7 Market Breakup by Region 5.8 Market Forecast 6 Market Breakup by Disease Type 6.1 Evaporative Dry Eye Syndrome 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Aqueous Dry Eye Syndrome 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Drug Type 7.1 Lubricant Eye Drops 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Anti-inflammatory Drugs 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Autologous Serum Eye Drops 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Product 8.1 Liquid Drops 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Gel 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Liquid Wipes 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Eye Ointment 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Others 8.5.1 Market Trends 8.5.2 Market Forecast 9 Market Breakup by Distribution Channel 9.1 Retail Pharmacies 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Hospital Pharmacies 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Online Pharmacies 9.3.1 Market Trends 9.3.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 Market Trends 10.1.2 Market Forecast 10.2 Europe 10.2.1 Market Trends 10.2.2 Market Forecast 10.3 Asia Pacific 10.3.1 Market Trends 10.3.2 Market Forecast 10.4 Middle East and Africa 10.4.1 Market Trends 10.4.2 Market Forecast 10.5 Latin America 10.5.1 Market Trends 10.5.2 Market Forecast 11 Global Dry Eye Syndrome Industry: SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats 12 Global Dry Eye Syndrome Industry: Value Chain Analysis 13 Global Dry Eye Syndrome Industry: Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes 14 Global Dry Eye Syndrome Industry: Price Analysis 14.1 Price Indicators 14.2 Price Structure 14.3 Margin Analysis 15 Manufacturing Process 15.1 Product Overview 15.2 Raw Material Requirements 15.3 Manufacturing Process 15.4 Key Success and Risk Factors 16 Competitive Landscape 16.1 Market Structure 16.2 Key Players 16.3 Profiles of Key Players 16.3.1 Novartis AG 16.3.2 Allergan plc. 16.3.3 Otsuka Holdings Co., Ltd. 16.3.4 Santen Pharmaceutical Co., Ltd. 16.3.5 Nicox S.A. 16.3.6 Auven Therapeutics 16.3.7 Akorn, Inc. 16.3.8 Bausch + Lomb 16.3.9 Alimera Science 16.3.10 GlaxoSmithKline plc |
Market Breakup by Disease Type
Market Breakup by Drug Type
Market Breakup by Product
Market Breakup by Distribution Channel
Market Breakup by Region